KRAS and neoplasm: While PDAC is characterized by KRAS-dependent signaling activation and loss of tumor suppressor function through TP53 mutations, ITPN shows enrichment of alterations affecting growth factor signaling pathways through FGFR2 fusions and PI3K pathway activation.